About Illumacell
Illumacell is a company based in Waterloo (Canada) founded in 2008 by Tom Kerber. Illumacell offers products and services including Illumacell Light Device and Wall-of-Light Technology. Illumacell operates in a competitive market with competitors including PhotoPharmics, CranioVation, Lumeda, Adgero Biopharma and SpectraCure, among others.
- Headquarter Waterloo, Canada
- Founders Tom Kerber
- SectorsHealthcare
- Email••••••••
- Website illumacell.com
- Legal Name Illumacell Inc
- Investors
Products & Services of Illumacell
Illumacell offers a comprehensive portfolio of products and services, including Illumacell Light Device and Wall-of-Light Technology.
Delivers photodynamic therapy to destroy cancer cells using light.
Provides controlled light for targeted cancer treatment protocols.
Funding Insights of Illumacell
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Illumacell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | – | Seed | – | Accelerator Centre | – |
1 investors in total: 1 institutional.
Investors in Illumacell
Illumacell has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Accelerator Centre.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Startups are built and accelerated in a structured studio environment. | – | acceleratorcentre.com | Waterloo, Canada |
Investor details for Illumacell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Illumacell
1 people are tracked at Illumacell (1 in leadership).
| Name | Role | Group |
|---|---|---|
Tom Kerber | Founder & CTO | Leadership |
Complete people profiles for Illumacell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Illumacell
2 dated milestones of Illumacell across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Illumacell is founded.
- Funding First funding round.
Competitors of Illumacell
Illumacell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PhotoPharmics, CranioVation, Lumeda, Adgero Biopharma and SpectraCure, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| photopharmics.com | 2011 | American Fork, United States | $43.44M | – | Non-invasive phototherapy for Parkinson's disease is developed. | |
| craniovation.com | 2017 | Rochester, United States | $7.61M | – | Minimally invasive devices for brain tumor treatment are provided. | |
| lumedainc.com | 2020 | Rocky Hill, United States | $5.34M | 10 | Photodynamic therapy device for lung cancer treatment is developed. | |
| adgerobiopharm.com | 2012 | Princeton, United States | $5.52M | – | Photodynamic therapy for cutaneous metastatic breast cancer is developed. | |
| spectracure.com | 2003 | Lund, Sweden | – | – | Developer of Interstitial photo dynamic therapy for solid tumours | |
| photolitec.org | 2010 | Buffalo, United States | $5M | – | Supplies photosensitizing compounds for tumor imaging and photodynamic cancer therapy. | |
| illumimedical.com | 2023 | Nagoya, Japan | $2.26M | – | Photodynamic therapy devices for cancer treatment are developed. | |
| impactbiotech.com | 2022 | Ness Ziona, Israel | – | – | Developer of a drug delivery platform for the treatment of solid tumors |
Detailed competitors of Illumacell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Illumacell
10 companies that operate in the same segment as Illumacell (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Illumacell
Illumacell was founded in 2008 and raised its 1st funding round 14 years after it was founded.
Illumacell is headquartered in Waterloo, Canada. It is registered at Waterloo, Ontario, Canada.
Provider of medical light technology for photodynamic therapy cancer treatment. It offers medical light technology to selectively treat cancerous tissue or tumors, offering a non-invasive and targeted approach that provide deep penetration and phototoxic effect in target tissues.
Illumacell's top competitors include PhotoPharmics, ImPact Biotech and Adgero Biopharma.
Illumacell offers Illumacell Light Device and Wall-of-Light Technology.
Illumacell has 1 investor. Key investors include Accelerator Centre.
Illumacell operates through Illumacell Inc.